CDK2 and cancer: To test whether CDK2 KO mice were protected against cisplatin ototoxicity in vivo, we adopted a protocol in which multiple low-dose cisplatin treatments were administered to mimic the cisplatin regimens used to treat patients with cancer (Roy et al., 2013).